Summary
Background
Systemic therapies are typically combined with topical corticosteroids for the management of moderate-to-severe atopic dermatitis. Upadacitinib is an oral Janus kinase (JAK) inhibitor with greater inhibitory potency for JAK1 than JAK2, JAK3, or tyrosine kinase 2 that is being tested for atopic dermatitis. We aimed to assess the efficacy and safety of upadacitinib plus topical corticosteroids compared with placebo for the treatment of moderate-to-severe atopic dermatitis.
Methods
In this randomised, double-blind, placebo-controlled, phase 3 trial (AD Up) adults (aged 18–75 years) and adolescents (aged 12–17 years) with chronic atopic dermatitis that was moderate to severe (≥10% of body surface area affected, Eczema Area and Severity Index [EASI] score of ≥16, validated Investigator's Global Assessment for atopic dermatitis [vIGA-AD] score of ≥3, and weekly average Worst Pruritus Numerical Rating Scale score of ≥4 at baseline) were enrolled at 171 clinical centres across 22 countries in the Asia-Pacific region, Europe, the Middle East, North America, and Oceania. Patients were randomly assigned (1:1:1) to receive upadacitinib 15 mg, upadacitinib 30 mg, or placebo once daily, all in combination with topical corticosteroids for 16 weeks. Randomisation was done using an interactive response technology system, stratified by baseline disease severity, geographical region, and age. Study investigators, study site personnel, and patients were masked to study treatment. The coprimary endpoints were the proportion of patients who had achieved at least a 75% reduction in EASI score from baseline (EASI-75) and the proportion of patients who had achieved a vIGA-AD response (defined as a vIGA-AD score of 0 [clear] or 1 [almost clear] with ≥2 grades of improvement from baseline) at week 16. Efficacy was analysed in the intention-to-treat population and safety was analysed in all patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, NCT03568318, and is active, but not recruiting.
Findings
Between Aug 9, 2018, and Dec 20, 2019, 901 patients were randomly assigned to receive upadacitinib 15 mg plus topical corticosteroids (n=300), upadacitinib 30 mg plus topical corticosteroids (n=297), or placebo plus topical corticosteroids (n=304). At week 16, the proportion of patients who had achieved EASI-75 was significantly higher in the upadacitinib 15 mg plus topical corticosteroid group (194 [65%] of 300 patients) and the upadacitinib 30 mg plus topical corticosteroids group (229 [77%] of 297 patients) than the placebo group (80 [26%] of 304 patients; adjusted difference in EASI-75 response rate vs placebo, 38·1% [95% CI 30·8–45·4] for the upadacitinib 15 mg group and 50·6% [43·8–57·4] for the upadacitinib 30 mg group; p<0·0001 for both doses). The proportion of patients who had achieved a vIGA-AD response at week 16 was significantly higher in the upadacitinib 15 mg plus topical corticosteroid group (119 [40%] patients) and upadacitinib 30 mg plus topical corticosteroid group (174 [59%] patients) than the placebo group (33 [11%] patients; adjusted difference in vIGA-AD response vs placebo, 28·5% [22·1–34·9] for the upadacitinib 15 mg group and 47·6% [41·1–54·0] for the upadacitinib 30 mg group; p<0·0001 for both doses). During the double-blind period, upadacitinib 15 and 30 mg were well tolerated in combination with topical corticosteroids. The most frequently reported treatment-emergent adverse events (≥5% in any treatment group) were acne, nasopharyngitis, upper respiratory tract infection, oral herpes, elevation of blood creatine phosphokinase levels, headache, and atopic dermatitis. The incidence of acne was higher in the upadacitinib 15 mg (30 [10%] of 300 patients) and upadacitinib 30 mg (41 [14%] of 297 patients) groups than the placebo group (six [2%] of 304 patients). The incidence of adverse events leading to discontinuation of study drug (four [1%] patients in the upadacitinib 15 mg plus topical corticosteroids group, four [1%] patients in the upadacitinib 30 mg plus topical corticosteroids group, and seven [2%] patients in the placebo plus topical corticosteroids group) and serious adverse events (seven [2%] patients, four [1%] patients, and nine [3%] patients) were similar among treatment groups. No deaths were reported in any treatment group.
Interpretation
Upadacitinib plus topical corticosteroids was well tolerated and superior to placebo plus topical corticosteroids. Upadacitinib as combination therapy had a positive benefit–risk profile in adults and adolescents with moderate-to-severe atopic dermatitis.
Funding
AbbVie.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Access any 5 articles from the Lancet Family of journals
Subscribe:
Subscribe to The LancetAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- 1.The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions.J Invest Dermatol. 2014; 134: 1527-1534
- 2.Atopic dermatitis.Nat Rev Dis Primers. 2018; 4: 1
- 3.Shifting paradigms in the immunology of atopic dermatitis.J Allergy Clin Immunol. 2020; 145: 1360-1362
- 4.Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies.J Am Acad Dermatol. 2014; 71: 116-132
- 5.Drug survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis.Br J Dermatol. 2015; 172: 1621-1627
- 6.Drug survival for azathioprine and enteric-coated mycophenolate sodium in a long-term daily practice cohort of adult patients with atopic dermatitis.Br J Dermatol. 2016; 175: 199-202
- 7.Two phase 3 trials of dupilumab versus placebo in atopic dermatitis.N Engl J Med. 2016; 375: 2335-2348
- 8.Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.Lancet. 2017; 389: 2287-2303
- 9.Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).Br J Dermatol. 2020; 184: 437-449
- 10.Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial.Br J Dermatol. 2020; 184: 450-463
- 11.Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials.Br J Dermatol. 2020; 183: 242-255
- 12.Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial.JAMA Dermatol. 2020; 156: 1333-1343
- 13.JAK inhibitors for atopic dermatitis: an update.Am J Clin Dermatol. 2019; 20: 181-192
- 14.In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494).BMC Rheumatol. 2018; 2: 23
- 15.The role of fluorine in medicinal chemistry.J Enzyme Inhib Med Chem. 2007; 22: 527-540
- 16.Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial.J Allergy Clin Immunol. 2020; 145: 877-884
- 17.Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.Lancet. 2021; (published online May 20.)
- 18.Diagnostic features of atopic dermatitis.Acta Dermatovener. 1980; 60: 44-47
- 19.The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis.J Am Acad Dermatol. 2020; 83: 839-846
- 20.RINVOQ (updacitinib) extended-release tablets full prescribing information.
- 21.Guidance for industry: drug-induced liver injury: premarketing clinical evaluation.
- 22.Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately to severely active rheumatoid arthritis (SELECT-EARLY): a randomized, double-blind, active-comparator, multi-center, multi-country trial.Arthritis Rheumatol. 2020; 72: 1607-1620
- 23.Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.Lancet. 2019; 393: 2303-2311
- 24.Adverse effects of topical glucocorticosteroids.J Am Acad Dermatol. 2006; 54: 1-15
- 25.No association between atopic dermatitis and acne vulgaris in the general population.J Eur Acad Dermatol Venereol. 2020; 35: 275-278
- 26.Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial.JAMA Dermatol. 2020; 156: 863-873
- 27.Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial.Lancet. 2020; 396: 110-120
- 28.Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis.J Eur Acad Dermatol Venereol. 2020; 34: 192-201
- 29.Eczema herpeticum: clinical and pathophysiological aspects.Clin Rev Allergy Immunol. 2020; 59: 1-18
- 30.Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases.J Am Acad Dermatol. 2003; 49: 198-205
- 31.Neutrophils as emerging therapeutic targets.Nat Rev Drug Discov. 2020; 19: 253-275
- 32.
Queeney K, Housley W, Sokolov J, Long A. Elucidating the mechanism underlying creatine phosphokinase upregulation with upadacitinib. Annual European Congress of Rheumatology; Madrid; June 12–15, 2019 (abstr FRI0131).
Article info
Publication history
Published: May 20, 2021
Identification
Copyright
© 2021 Elsevier Ltd. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Articles
- Treatment of atopic dermatitis with biologics and Janus kinase inhibitors
- Department of Error
- Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2021; 397: 2169–81—In figure 1 of this Article, in the green boxes for medium and low potency topical corticosteroids, twice daily should have read once daily. These corrections have been made to the online version as of June 17, 2021.
- Full-Text
- Department of Error
- Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2021; 397: 2169–81—In this Article, the key was incorrect in figure 4. In the Discussion, the first sentence of the second paragraph should have read “A higher proportion of patients given placebo in combination with topical corticosteroids in this study had a response than did patients given placebo in the Measure Up 1 and Measure Up 2 studies”; and the fifth sentence of the fourth paragraph should have read “AD Up is ongoing and will provide more than 5 years of efficacy and safety data for upadacitinib in combination with topical corticosteroids when complete”.
- Full-Text
Related Clinics
View full text
